Phase II Study of Vismodegib in Patients With <i>SMO-</i> or <i>PTCH1</i> -Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Netwo
Vismodegib was well tolerated with mainly grade 1-2 toxicities, but it did not meet the primary end point. Select patients with specific <i>SMO</i> and <i>PTCH1</i> alterations had notable responses, warranting further comprehensive molecular analyses to elucidate resistance mechanisms.
Authors
- Percy Ivy
- Alice P. Chen (ORCID: https://orcid.org/0000-0002-2919-4326)
- Li Chen (ORCID: https://orcid.org/0000-0001-7973-5912)
- Lyndsay N. Harris (ORCID: https://orcid.org/0000-0002-9774-6719)
- Chris Karlovich (ORCID: https://orcid.org/0000-0002-4617-2161)
- Keith T. Flaherty (ORCID: https://orcid.org/0000-0002-3402-0478)
- Peter James O'Dwyer (ORCID: https://orcid.org/0000-0002-9302-4073)
- Larry Rubinstein (ORCID: https://orcid.org/0000-0002-9720-9737)
- P. Mickey Williams
- David R. Patton (ORCID: https://orcid.org/0000-0003-3855-0166)
- Alan Loh Ho (ORCID: https://orcid.org/0000-0002-6885-3742)
- Jennifer S. LoCoco (ORCID: https://orcid.org/0000-0002-7437-5177)
- Lisa M. McShane (ORCID: https://orcid.org/0000-0001-8195-3206)
- Carlos L. Arteaga (ORCID: https://orcid.org/0000-0003-0870-9586)
- Barbara A. Conley (ORCID: https://orcid.org/0000-0002-1445-1684)
- Anne S. Tsao (ORCID: https://orcid.org/0000-0003-0505-6639)
- Sorena Rahmanian (ORCID: https://orcid.org/0000-0002-5692-163X)
- James V. Tricoli (ORCID: https://orcid.org/0000-0003-3975-8516)
- Robert J. Gray (ORCID: https://orcid.org/0000-0002-5724-4917)
- Stanley R. Hamilton (ORCID: https://orcid.org/0000-0002-8331-1052)
- Zihe Song
- Naoko Takebe (ORCID: https://orcid.org/0000-0002-5790-4954)
- Janice M. Mehnert (ORCID: https://orcid.org/0000-0001-9492-9264)
- Biswajit Das (ORCID: https://orcid.org/0000-0001-7225-2926)
- Jennifer L. Silhavy
- Victoria Wang
- Raid Ajumally
Institutions
- City Of Hope National Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Illumina (United States) (US)
- Hospital of the University of Pennsylvania (US)
- Pennsylvania Hospital (US)
- Massachusetts General Hospital (US)
- Dana-Farber Cancer Institute (US)
- Ralph Lauren Center for Cancer Care and Prevention (US)
- National Cancer Institute (UA)
- Frederick National Laboratory for Cancer Research (US)
- National Cancer Institute (MY)
- National Cancer Institute (US)
- University of Oklahoma Health Sciences Center (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1200/po-25-00119
- Primary Topic
- Hedgehog Signaling Pathway Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00